Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28311259 | 0.98 | TAAR1 (0.55) | TAAR1ESR2CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL28042449 | 0.92 | TAAR1 (0.50) | TAAR1ESR2CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL11973522 | 0.83 | MEN1 (0.48) | TAAR1ESR2CYP3A4NISCHHSD17B1 | |
| SCHEMBL198702 | 0.83 | TAAR1 (0.68) | TAAR1ESR2CYP17A1CYP3A4CYP11B1 | |
| Biphenyl SCHEMBL25183774 | 0.80 | TAAR1 (0.67) | TAAR1ESR2CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL29451178 | 0.80 | TAAR1 (0.67) | TAAR1ESR2CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL200605 | 0.80 | TAAR1 (0.67) | TAAR1ESR2CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL16605626 | 0.80 | TAAR1 (0.65) | TAAR1ESR2CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL29628985 | 0.80 | TAAR1 (0.65) | TAAR1ESR2CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL16605628 | 0.80 | TAAR1 (0.65) | TAAR1ESR2CYP17A1CYP3A4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396465-A | Novel oxazole derivative for preventing or treating allergic diseases and pharmaceutical composition containing the same | 阿斯克里斯有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-115385956-A | Biaryl diphosphine ligands and transition metal complexes thereof | 东莞市均成高新材料有限公司 | 2022-11-25 | — | — | CN | claimed |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | claimed |
| CN-113214104-A | Method for synthesizing aromatic acetamide | 浙江工业大学 | 2021-08-06 | — | — | CN | claimed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | claimed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | claimed |
| WO-2015022293-A2 | 1,3-(HET)ARYL-SUBSTITUTED PYRAZOLE COMPOUNDS | BASF SE (DE) | 2015-02-19 | — | — | WO | claimed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | claimed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | claimed |
| EP-2160187-B1 | SPIROINDALONES | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | claimed |
| US-6358981-B1 | FOR THERAPY OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | claimed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | claimed |
| JP-2001511781-A | — | — | 2001-08-14 | — | — | JP | claimed |
| WO-2001019795-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| CN-1251523-A | Sulfonamide derivatives | LILLY CO ELI (US) | 2000-04-26 | — | — | CN | claimed |
| EP-0980864-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 2000-02-23 | — | — | EP | claimed |
| WO-2000006539-A1 | ALKENYL SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
| WO-2000006157-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | claimed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | TAAR1 150/4885ESR2 903/4885CYP17A1 2613/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | TAAR1 129/4885ESR2 543/4885CYP17A1 2217/4885 |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | TAAR1 2754/4885ESR2 694/4885CYP17A1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.